

REFERENCE:

1. Yan W., Zhang G. Molecular characteristics and clinical significance of 12 fusion genes in acute promyelocytic leukemia: A systematic review. *Acta Haematol.* 2016;136:1–15
2. Langabeer S.E., Preston L., Kelly J., Goodyer M., Elhassadi E., Hayat A. Molecular profiling: A case of ZBTB16-RARA acute promyelocytic leukemia. *Case Rep. Hematol.* 2017;2017:1–4.
3. Licht J., Chomienne C., Goy A., Chen A., Scott A., Head D., Michaux J., Wu Y., deBlasio A., Miller W.J. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17) *Blood.* 1995;85:1083–1094.
4. Sainty D., Liso V., Fenu S., Mancini M., Duchayne E., Mahon F.-X., Gutierrez N., Birg F., Biondi A., Grimwade D., et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. *Blood J. Am. Soc. Hematol.* 2000;96:10.
5. Dowse R.T., Ireland R.M. Variant ZBTB16-RARA translocation: Morphological changes predict cytogenetic variants of APL. *Blood.* 2017;129:2038.
6. Jovanovic J.V., Rennie K., Culligan D., Peniket A., Lennard A., Harrison J., Vyas P., Grimwade D. Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia. *Front. Oncol.* 2011;1:35.